A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection

Journal of Hepatology

Volumn 58, Issue 5, 2013, Pages 853-860

  Liu, Jessica ^a,b   Lee, Mei Hsuan ^b,c   Batrla Utermann, Richard ^d   Jen, Chin Lan ^b   Iloeje, Uchenna H ^e   Lu, Sheng Nan ^f   Wang, Li Yu ^g   You, San Lin ^b   Hsiao, Chuhsing K ^a   Yang, Hwai I ^b,h,i   Chen, Chien Jen ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d Roche Diagnostics Ltd   (Switzerland)

^e BRISTOL MYERS SQUIBB   (United States)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g Department of Optometry   (Taiwan)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chronic hepatitis B; Prediction; Seroclearance

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ASSESSMENT; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM;

ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SEROLOGY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84876286013     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.12.006     Document Type: Article

References (32)

1. D. Lavanchy, and B. Hepatitis Virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2004 97 107
2. W.M. Lee, and B. Hepatitis Virus infection N Engl J Med 337 1997 1733 1745
3. Y.F. Liaw, and C.M. Chu Hepatitis B virus infection Lancet 373 2009 582 592
4. H.I. Yang, H.L. Hung, M.H. Lee, J. Liu, C.L. Jen, and J. Su Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B Clin Gastroenterol Hepatol 10 2012 527 534 e521-e522.
5. H.I. Yang, S.N. Lu, Y.F. Liaw, S.L. You, C.A. Sun, and L.Y. Wang Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 2002 168 174
6. C.M. Chu, and Y.F. Liaw Hepatitis B surface antigen seroclearance during chronic HBV infection Antivir Ther 15 2010 133 143
7. EASL EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
8. J. Liu, H.I. Yang, M.H. Lee, S.N. Lu, C.L. Jen, and L.Y. Wang Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study Gastroenterology 139 2010 474 482
9. Y.F. Liaw Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review Hepatology 53 2011 2121 2129
10. T. Nguyen, P. Desmond, and S. Locarnini The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B Hepatol Int 3 2009 5 15
11. H.L. Chan, V.W. Wong, A.M. Tse, C.H. Tse, A.M. Chim, and H.Y. Chan Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response Clin Gastroenterol Hepatol 5 2007 1462 1468
12. A.J. Thompson, T. Nguyen, D. Iser, A. Ayres, K. Jackson, and M. Littlejohn Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers Hepatology 51 2010 1933 1944
13. J. Jaroszewicz, B. Calle Serrano, K. Wursthorn, K. Deterding, J. Schlue, and R. Raupach Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective J Hepatol 52 2010 514 522
14. V. Rijckborst, B.E. Hansen, Y. Cakaloglu, P. Ferenci, F. Tabak, and M. Akdogan Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels Hepatology 52 2010 454 461
15. M.J. Sonneveld, V. Rijckborst, C.A. Boucher, B.E. Hansen, and H.L. Janssen Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline Hepatology 52 2010 1251 1257
16. V. Rijckborst, B.E. Hansen, P. Ferenci, M.R. Brunetto, F. Tabak, and Y. Cakaloglu Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a J Hepatol 56 2012 1006 1011
17. M.R. Brunetto, F. Oliveri, P. Colombatto, F. Moriconi, P. Ciccorossi, and B. Coco Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers Gastroenterology 139 2010 483 490
18. H. Park, J.M. Lee, J.H. Seo, H.S. Kim, S.H. Ahn, and Y. Kim do Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers Liver Int 32 2012 796 802
19. T.C. Tseng, C.J. Liu, H.C. Yang, T.H. Su, C.C. Wang, and C.L. Chen Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load Hepatology 55 2012 68 76
20. H.L. Chan, G.L. Wong, C.H. Tse, H.Y. Chan, and V.W. Wong Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients J Infect Dis 204 2011 408 414
21. T.C. Tseng, C.J. Liu, T.H. Su, C.C. Wang, C.L. Chen, and P.J. Chen Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters Gastroenterology 141 2011 517 525 525, e511-e512
22. W.K. Seto, D.K. Wong, J. Fung, I.F. Hung, D.Y. Fong, and J.C. Yuen A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance Hepatology 56 2012 812 819
23. C.J. Chen, U.H. Iloeje, and H.I. Yang Long-term outcomes in hepatitis B: the REVEAL-HBV study Clin Liver Dis 11 2007 797 816 viii
24. S. Durrleman, and R. Simon Flexible regression models with cubic splines Stat Med 8 1989 551 561
25. L.M. Sullivan, J.M. Massaro, and R.B. D'Agostino Sr. Presentation of multivariate data for clinical use: the Framingham study risk score functions Stat Med 23 2004 1631 1660
26. H.I. Yang, M. Sherman, J. Su, P.J. Chen, Y.F. Liaw, and U.H. Iloeje Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection J Clin Oncol 28 2010 2437 2444
27. H.I. Yang, M.F. Yuen, H.L. Chan, K.H. Han, P.J. Chen, and D.Y. Kim Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score Lancet Oncol 12 2011 568 574
28. P.J. Heagerty, T. Lumley, and M.S. Pepe Time-dependent ROC curves for censored survival data and a diagnostic marker Biometrics 56 2000 337 344
29. S.H. Ahn, H.L. Chan, P.J. Chen, J. Cheng, M.K. Goenka, and J. Hou Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions Hepatol Int 4 2010 386 395
30. J. Simonetti, L. Bulkow, B.J. McMahon, C. Homan, M. Snowball, and S. Negus Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus Hepatology 51 2010 1531 1537
31. J. Liu, M.H. Lee, R. Batrla, C.L. Jen, U.H. Iloeje, and S.N. Lu Differences in the role of quantitative hepatitis B surface antigen between HBeAg seropositive and seronegative individuals with chronic hepatitis B J Hepatol 56 2012 S187
32. T. Volz, M. Lutgehetmann, P. Wachtler, A. Jacob, A. Quaas, and J.M. Murray Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients Gastroenterology 133 2007 843 852